H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Cerevel Therapeutics to $48 from $50 and keeps a Buy rating on the shares post the Q3 results.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CERE:
- Cerevel Therapeutics initiated with a Buy at Loop Capital
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Cerevel Therapeutics initiated with a Buy at BofA
- Cerevel Therapeutics to Report Third Quarter 2022 Financial Results and Pipeline Update on Tuesday, November 8, 2022
- Cantor starts ‘uniquely differentiated’ Cerevel with Overweight, $41 target